Service Utilization and Costs Associated With Switching to Risperidone from Previous Treatment with Typical Antipsychotic Agents

作者: J. Tan , H. Habil , M.A.S. Ayu , A. Hatim

DOI:

关键词:

摘要: This study determined medical service utilization and costs associated with switching to risperidone from previous treatment typical antipsychotic agents.  62 adult outpatients diagnosed schizophrenia were identified pharmacy records, complete information regarding for one year before after risperidone. Information on hospitalization, use of day care hospital, electroconvulsive therapy, emergency department, outpatient clinic services functional parameters collected. Cost treatment, cost unemployment lost productivity due suicide calculated. The results showed significant fewer hospitalization days, ECT sessions department visits observed (p<.05). total was 88.8% higher than during the agents.

参考文章(49)
John M. Kane, Treatment adherence and long-term outcomes. Cns Spectrums. ,vol. 12, pp. 21- 26 ,(2007) , 10.1017/S1092852900026304
B R Sommer, P R Finley, G H Brunson, B L Lum, J L Corbitt, Risperidone: clinical outcome predictors and cost-effectiveness in a naturalistic setting. Psychopharmacology Bulletin. ,vol. 34, pp. 75- 81 ,(1998)
Addington De, Chouinard G, Remington G, Bloom D, Albright P, Jones B, Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clinical Therapeutics. ,vol. 15, pp. 917- 926 ,(1993)
JF Guest, Eva Lindstrom, WM Hart, RF Cookson, Pharmacoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia British journal of Medical Economics. ,vol. 10, pp. 59- ,(1996)
Zhongyun Zhao, Madhav Namjoshi, Beth L Barber, Danielle L Loosbrock, Sandra L Tunis, Baojin Zhu, Alan Breier, Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database. CNS Drugs. ,vol. 18, pp. 157- 164 ,(2004) , 10.2165/00023210-200418030-00002
Roshni Mangalore, Martin Knapp, Cost of schizophrenia in England Journal of Mental Health Policy and Economics. ,vol. 10, pp. 23- 41 ,(2007)
M. Obradovic, A. Mrhar, M. Kos, Cost‐effectiveness of antipsychotics for outpatients with chronic schizophrenia International Journal of Clinical Practice. ,vol. 61, pp. 1979- 1988 ,(2007) , 10.1111/J.1742-1241.2007.01431.X
Simon Gilbody, Anne-Marie Bagnall, Lorna Duggan, Arja Tuunainen, Risperidone versus other atypical antipsychotic medication for schizophrenia Cochrane Database of Systematic Reviews. ,vol. 9, pp. 002306- ,(2016) , 10.1002/14651858.CD002306.PUB2
Alp Üçok, Aslıhan Polat, Sibel Çakır, Aysun Genç, One year outcome in first episode schizophrenia. Predictors of relapse. European Archives of Psychiatry and Clinical Neuroscience. ,vol. 256, pp. 37- 43 ,(2006) , 10.1007/S00406-005-0598-2
Martin Knapp, Schizophrenia costs and treatment cost-effectiveness Acta Psychiatrica Scandinavica. ,vol. 102, pp. 15- 18 ,(2000) , 10.1046/J.1467-0658.2001.00137.X-I1